Pharma in 2025: Stronger Risk Management of Supply Chains

Digital transformation, increased outsourcing of manufacturing and supply, and research and development changes all add to this complexity. And risks from global politics, extreme weather, military conflict, pandemics, quality or compliance issues, interruptions to international trade caused by incident, accident or dispute, industrial espionage, and statesponsored cyberattacks all play a role in raising risk profiles for pharmaceutical and chemical industry companies.

Because DACH pharma-chem businesses’ supply chains are connected locally and globally, the risk of disruptions is higher, making it harder to ensure compliance and security. There is no such thing as a typical pharmaceutical company. They range from the massive, multinational players with huge patent libraries to the single product, university spin-off start-ups. 

This diversity makes the market hard to measure. Pharmaceuticals are usually included in life sciences, which also includes food processing, biomedical technologies, and some healthcare services, and these make up more than half of the value of the sector.